Free Trial

CRISPR Therapeutics Sees Unusually Large Options Volume (NASDAQ:CRSP)

CRISPR Therapeutics logo with Medical background

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock traders acquired 10,886 call options on the company. This represents an increase of 49% compared to the average daily volume of 7,308 call options.

CRISPR Therapeutics Stock Down 2.6%

CRSP traded down $1.54 during trading on Friday, hitting $57.46. 1,047,453 shares of the company traded hands, compared to its average volume of 1,938,349. The firm has a market cap of $4.96 billion, a P/E ratio of -12.75 and a beta of 1.82. The stock's fifty day moving average is $42.15 and its 200 day moving average is $41.17. CRISPR Therapeutics has a one year low of $30.04 and a one year high of $63.68.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 20.08% and a negative net margin of 1,023.64%. During the same period in the prior year, the company posted ($1.43) EPS. The business's quarterly revenue was up 71.6% on a year-over-year basis. On average, equities research analysts forecast that CRISPR Therapeutics will post -5.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. The Goldman Sachs Group decreased their target price on CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. HC Wainwright restated a "buy" rating and set a $65.00 price target on shares of CRISPR Therapeutics in a report on Friday, June 27th. Piper Sandler reiterated an "overweight" rating and issued a $105.00 target price on shares of CRISPR Therapeutics in a report on Friday, June 27th. JMP Securities reaffirmed a "market outperform" rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research report on Friday, June 27th. Finally, Chardan Capital reiterated a "buy" rating and issued a $82.00 target price on shares of CRISPR Therapeutics in a report on Thursday, June 26th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $71.75.

Check Out Our Latest Stock Report on CRISPR Therapeutics

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,932 shares of the firm's stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $35.94, for a total value of $141,316.08. Following the transaction, the insider directly owned 6,068 shares of the company's stock, valued at $218,083.92. This trade represents a 39.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.30% of the company's stock.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of large investors have recently made changes to their positions in CRSP. Magnetar Financial LLC bought a new position in CRISPR Therapeutics in the 4th quarter valued at $359,000. Baker BROS. Advisors LP lifted its position in CRISPR Therapeutics by 55.1% in the 4th quarter. Baker BROS. Advisors LP now owns 1,308,011 shares of the company's stock worth $51,483,000 after buying an additional 464,936 shares during the last quarter. Vanguard Group Inc. lifted its position in CRISPR Therapeutics by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company's stock worth $68,329,000 after buying an additional 10,579 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its holdings in shares of CRISPR Therapeutics by 14.3% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 39,189 shares of the company's stock valued at $1,334,000 after purchasing an additional 4,914 shares during the last quarter. Finally, Green Alpha Advisors LLC lifted its stake in shares of CRISPR Therapeutics by 132.9% in the 1st quarter. Green Alpha Advisors LLC now owns 57,361 shares of the company's stock valued at $1,952,000 after acquiring an additional 32,732 shares during the last quarter. 69.20% of the stock is owned by institutional investors.

About CRISPR Therapeutics

(Get Free Report)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

See Also

Should You Invest $1,000 in CRISPR Therapeutics Right Now?

Before you consider CRISPR Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.

While CRISPR Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines